Standout Papers

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocell... 2017 2026 2020 2023 322
  1. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial (2017)
    Tim Meyer, Richard Fox et al. ˜The œLancet. Gastroenterology & hepatology

Immediate Impact

1 by Nobel laureates 1 from Science/Nature 134 standout
Sub-graph 1 of 17

Citing Papers

The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial
2025 Standout
Digestive cancers: mechanisms, therapeutics and management
2025 Standout
10 intermediate papers

Works of Clive Stubbs being referenced

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
2017 Standout
Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.
2017

Author Peers

Author Last Decade Papers Cites
Clive Stubbs 34 17 207 309 172 16 541
Zhi-Ping Yan 26 2 187 390 89 24 525
Yoshinori Urano 7 32 206 214 78 21 592
Howard H. Mizrachi 3 2 175 199 121 18 565
Jean Frédéric Blanc 3 4 279 264 167 20 578
Nyan L. Latt 10 3 199 175 105 24 514
Alexandra Heurgué 8 1 99 311 150 17 486
Philippe Porée 5 1 122 281 49 16 512
Chung-Ru Lai 28 3 139 407 90 19 602
Joanne Wing Yan Chiu 4 2 79 188 391 22 613
Wanli Wang 13 3 217 111 336 19 600

All Works

Loading papers...

Rankless by CCL
2026